Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
74 patients between the ages of 6 and 22 with cHL treated with cPT after systemic therapy (ST) were included.
I · Intervention 중재 / 시술
cPT for R/R disease
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] cPT is an effective and well-tolerated treatment for young patients with cHL, demonstrating excellent 10-year OS and RFS, even for those treated at relapse. These findings support cPT as a treatment modality, warranting further studies to assess long-term outcomes.
[PURPOSE] Classical Hodgkin lymphoma (cHL) is associated with favorable prognosis and high overall survival (OS).
- 추적기간 5.5 years
APA
Martir-Vargas D, Indelicato DJ, et al. (2026). Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.. International journal of particle therapy, 19, 101295. https://doi.org/10.1016/j.ijpt.2025.101295
MLA
Martir-Vargas D, et al.. "Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.." International journal of particle therapy, vol. 19, 2026, pp. 101295.
PMID
41561729 ↗
Abstract 한글 요약
[PURPOSE] Classical Hodgkin lymphoma (cHL) is associated with favorable prognosis and high overall survival (OS). Consolidative proton therapy (cPT) represents a modality recommended for young patients due to its reduction in exit dose, with a goal to minimize late effects. We present outcomes of pediatric patients with cHL receiving cPT at initial diagnosis or relapse/refractory (R/R) disease.
[MATERIALS AND METHODS] From 10/2007 to 12/2022, 74 patients between the ages of 6 and 22 with cHL treated with cPT after systemic therapy (ST) were included. Risk groups were classified by ST into low, intermediate, and high risk. Involved-site radiotherapy was used for most patients (90%). OS and relapse-free survival (RFS) were estimated using the Kaplan-Meier method; crude cumulative incidence estimates were used to describe recurrence patterns.
[RESULTS] Median follow-up was 5.5 years (30% > 8 years). Sixty-one (82.4%) patients were treated at initial diagnosis, and 13 (17.6%) received cPT for R/R disease. Median age at diagnosis was 16 years (range, 6.3-21.7), with most being female (58.1%), nodular sclerosing subtype (82.4%), and bulky disease (78.4%). 10-year OS was 96% overall (97% initial, 92% R/R); 10-year RFS was 84% overall (82% initial, 92% R/R). 10-year RFS was 100%, 82%, and 72% for low, intermediate, and high-risk groups. Of the 61 patients treated for initial diagnosis, 8 experienced relapse, with 4 (6.6%) out-of-field & in-field, 3 (4.9%) out-of-field, and 1 (1.6%) in-field. Of the 13 patients treated for R/R disease, 1 experienced an out-of-field recurrence. One patient developed papillary thyroid carcinoma 11.9 years post-cPT (in-field); no other grade 3+ radiation-related late toxicities were observed.
[CONCLUSION] cPT is an effective and well-tolerated treatment for young patients with cHL, demonstrating excellent 10-year OS and RFS, even for those treated at relapse. These findings support cPT as a treatment modality, warranting further studies to assess long-term outcomes.
[MATERIALS AND METHODS] From 10/2007 to 12/2022, 74 patients between the ages of 6 and 22 with cHL treated with cPT after systemic therapy (ST) were included. Risk groups were classified by ST into low, intermediate, and high risk. Involved-site radiotherapy was used for most patients (90%). OS and relapse-free survival (RFS) were estimated using the Kaplan-Meier method; crude cumulative incidence estimates were used to describe recurrence patterns.
[RESULTS] Median follow-up was 5.5 years (30% > 8 years). Sixty-one (82.4%) patients were treated at initial diagnosis, and 13 (17.6%) received cPT for R/R disease. Median age at diagnosis was 16 years (range, 6.3-21.7), with most being female (58.1%), nodular sclerosing subtype (82.4%), and bulky disease (78.4%). 10-year OS was 96% overall (97% initial, 92% R/R); 10-year RFS was 84% overall (82% initial, 92% R/R). 10-year RFS was 100%, 82%, and 72% for low, intermediate, and high-risk groups. Of the 61 patients treated for initial diagnosis, 8 experienced relapse, with 4 (6.6%) out-of-field & in-field, 3 (4.9%) out-of-field, and 1 (1.6%) in-field. Of the 13 patients treated for R/R disease, 1 experienced an out-of-field recurrence. One patient developed papillary thyroid carcinoma 11.9 years post-cPT (in-field); no other grade 3+ radiation-related late toxicities were observed.
[CONCLUSION] cPT is an effective and well-tolerated treatment for young patients with cHL, demonstrating excellent 10-year OS and RFS, even for those treated at relapse. These findings support cPT as a treatment modality, warranting further studies to assess long-term outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience.